Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$14.64 -0.4%	$14.41	$12.79 ▼ $55.70	$1.56B	0.98	2.16 million shs	1.10 million shs
CDTX Cidara Therapeutics	$67.49 +3.8%	$52.82	$10.14 ▼ $69.36	$1.65B	1.18	425,657 shs	661,938 shs
IMCR Immunocore	$32.67 +0.6%	$33.33	$23.15 ▼ $39.33	$1.64B	0.77	315,491 shs	382,254 shs
IVA Inventiva	$4.26 -7.0%	$3.42	$1.53 ▼ $4.70	$438.13M	0.73	32,207 shs	38,773 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	-3.27%	+1.77%	+6.23%	-5.14%	-64.23%
CDTX Cidara Therapeutics	+5.76%	+2.81%	+13.99%	+153.04%	+402.16%
IMCR Immunocore	+0.46%	-1.55%	-12.02%	+4.10%	-12.43%
IVA Inventiva	+2.69%	+13.93%	+42.68%	+46.33%	+89.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHVN Biohaven	3.7951 of 5 stars	4.5	3.0	0.0	2.8	2.5	0.6
CDTX Cidara Therapeutics	3.504 of 5 stars	2.6	3.0	4.6	2.0	1.7	0.0
IMCR Immunocore	1.9598 of 5 stars	3.3	1.0	0.0	2.8	2.5	0.0
IVA Inventiva	3.3651 of 5 stars	3.4	5.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	3.07	Buy	$54.23	270.53% Upside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-4.96% Downside
IMCR Immunocore	2.50	Moderate Buy	$58.00	77.53% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	144.13% Upside

Current Analyst Ratings Breakdown

Latest IVA, BHVN, IMCR, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	BHVN Biohaven	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$59.00 ➝ $60.00
8/12/2025	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $30.00
8/12/2025	BHVN Biohaven	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $50.00
8/12/2025	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$63.00 ➝ $54.00
8/12/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $52.00
8/12/2025	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $49.00
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$1.27 per share	N/A
CDTX Cidara Therapeutics	$1.27M	1,347.67	N/A	N/A	$19.76 per share	3.42
IMCR Immunocore	$310.20M	5.31	N/A	N/A	$7.71 per share	4.24
IVA Inventiva	$9.95M	40.96	N/A	N/A	($1.21) per share	-3.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$846.42M	-$7.66	N/A	N/A	N/A	N/A	-270.65%	-143.70%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)

Latest IVA, BHVN, IMCR, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	BHVN Biohaven	-$1.94	-$1.94	N/A	-$1.94	$0.41 million	N/A
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	1.91	3.82	3.82
CDTX Cidara Therapeutics	N/A	16.45	16.45
IMCR Immunocore	1.01	5.89	5.86
IVA Inventiva	N/A	0.92	0.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
CDTX Cidara Therapeutics	35.82%
IMCR Immunocore	84.50%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	16.00%
CDTX Cidara Therapeutics	3.89%
IMCR Immunocore	10.40%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	105.79 million	88.86 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable

IVA, BHVN, IMCR, and CDTX Headlines

Recent News About These Companies

Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 72.9%

August 17, 2025 | marketbeat.com

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

August 12, 2025 | finance.yahoo.com

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

August 3, 2025 | marketbeat.com

Half-Year Review of Inventiva’s Liquidity Contract with Kepler ...

August 2, 2025 | morningstar.comM

Inventiva Announces Preliminary First-Half 2025 Financial Results

July 31, 2025 | theglobeandmail.com

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

July 31, 2025 | globenewswire.com

INVENTIVA: Inventiva Reports Preliminary 2025 First-Half Financial Information

July 30, 2025 | finanznachrichten.de

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

July 30, 2025 | finance.yahoo.com

Inventiva appoints new R&D president and regulatory affairs executive

July 11, 2025 | investing.com

Inventiva names Jason Campagna as President of R&D and Chief Medical ...

July 11, 2025 | finance.yahoo.com

Inventiva Strengthens Leadership Team Ahead of Key MASH Drug Milestones

July 10, 2025 | yahoo.com

Inventiva reshuffles leadership as it pushes lanifibranor closer to approval

July 10, 2025 | thepharmaletter.comT

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

July 9, 2025 | globenewswire.com

INVENTIVA: Inventiva receives $10 million milestone payment from CTTQ

July 8, 2025 | finanznachrichten.de

Inventiva receives $10 million milestone payment from CTTQ

July 7, 2025 | globenewswire.com

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients ... - The Manila Times

July 4, 2025 | manilatimes.netM

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

July 2, 2025 | globenewswire.com

Inventiva S.A. (IVA) Latest Stock News & Headlines - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

June 24, 2025 | msn.com

Inventiva appoints former Calliditas CEO to board of directors

June 11, 2025 | uk.investing.com

INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 11, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IVA, BHVN, IMCR, and CDTX Company Descriptions

Biohaven NYSE:BHVN

$14.64 -0.06 (-0.44%)

Closing price 03:59 PM Eastern

Extended Trading

$14.48 -0.16 (-1.07%)

As of 07:41 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Cidara Therapeutics NASDAQ:CDTX

$67.49 +2.46 (+3.78%)

Closing price 04:00 PM Eastern

Extended Trading

$68.24 +0.75 (+1.11%)

As of 07:59 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Immunocore NASDAQ:IMCR

$32.67 +0.18 (+0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$32.69 +0.02 (+0.06%)

As of 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Inventiva NASDAQ:IVA

$4.26 -0.32 (-6.99%)

Closing price 04:00 PM Eastern

Extended Trading

$4.32 +0.07 (+1.53%)

As of 07:13 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time